Biomea Fusion Inc.
BMEAHeld by 7 specialist biotech funds
High Convergence7 funds opened new positions. Next phase2 readout (icovamenib 100mg): Jun 2027. Short interest: 23.2% of float.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.